# Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation

Study · id `cardio:ct-nct04209959` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04209959](<https://clinicaltrials.gov/study/NCT04209959>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04209959

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT04209959. Randomized; single masking; primary purpose treatment. Start 2019-01-01 (actual); primary completion 2020-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT04209959, source copy `cardio:ctgov-nct04209959-2019-12-24`, retrieved 2026-10-26)
- Started: 2019-01-01 (actual) (ClinicalTrials.gov record NCT04209959, source copy `cardio:ctgov-nct04209959-2019-12-24`, retrieved 2026-10-26)
- Primary completion: 2020-01-01 (anticipated) (ClinicalTrials.gov record NCT04209959, source copy `cardio:ctgov-nct04209959-2019-12-24`, retrieved 2026-10-26)
- Completion: 2020-02-01 (anticipated) (ClinicalTrials.gov record NCT04209959, source copy `cardio:ctgov-nct04209959-2019-12-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04209959, source copy `cardio:ctgov-nct04209959-2019-12-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04209959-2019-12-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation
- Condition: Atrial Fibrillation
- Intervention (Drug): nifekalant
- Lead sponsor: Second Affiliated Hospital of Nanchang University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital of Nanchang University (`cardio:org-second-affiliated-hospital-of-nanchang-university`)

## Provenance

Content hash: b720d2f14ca570de13f697e1ab7aefd4216bb0d06e4944bba947f35733c2e7f7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
